- Home
- Equipment
- north america
- cancer as an environmental disease
Show results for
Refine by
Applications
- RNA Technology for Research Fellowship
- RNA Technology for Medical Areas of Focus Research
- RNA Technology for Product Pipeline Research
- RNA Technology for Clinical trials
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Isotopes for Medical
- Clean air solutions for allergens area
- Clean air solutions for pollution area
- Clean air solutions for bad odor area
- Clean air solutions for bacteria area
- Clean air solutions for virus area
Cancer As An Environmental Disease Equipment Supplied In North America
117 equipment items found
Manufactured by:Shine Technologies based inJanesville, WISCONSIN (USA)
SHINE Technologies’ production process results in molybdenum-99 that is of high quality and high purity, resulting in Mo-99 that has high specific activity and is ready for delivery to our medical customers. We believe our production of Mo-99 in the United States will contribute to the reliability of SHINE’s supply in a time of chronic shortages of medical ...
Manufactured by:ProImmune Ltd. based inOxford, UNITED KINGDOM
A clear solution to a long-standing problem. Detecting and targeting specific MHC-peptide complexes is of material interest for understanding many disease conditions better and for developing novel therapeutic interventions. It has been very challenging to develop antibodies that bind selectively to an MHC-peptide combination over a more general MHC ...
Manufactured by:AnaSpec based inFremont, CALIFORNIA (USA)
Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated zinc endopeptidases capable of digesting extracellular matrix components. MMP-9 (92-kDa gelatinase, collagenase-IV) is involved in a number of diseases such as cancer, angiogenesis, alopecia, and metastasis. MMP-9 is secreted as zymogen with prodomain, gelatin-binding domain consisting of three contiguous ...
by:LIXTE Biotechnology Holdings, Inc. based inPasadena, CALIFORNIA (USA)
We have also developed another class of compounds that are novel histone deacetylase inhibitors (HDACi). Designated as our LB-200 series of compounds, these have potential use in the prevention and treatment of neurodegenerative diseases. The series has the potential to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as Gaucher’s ...
Manufactured by:Blue Earth Diagnostics based inOxford, UNITED KINGDOM
Diagnostic nuclear medicine is a type of molecular imaging that uses very small amounts of radioisotopes attached to a targeting molecule (radiopharmaceutical1) to diagnose complex diseases such as cancer. Radiopharmaceuticals are able to show the physiological function of the body rather than just the anatomy. Changes in the biochemical activity of cells often characterises disease. For example, ...
Manufactured by:AMS Biotechnology (Europe) Ltd. based inAbingdon, UNITED KINGDOM
Breast cancer with adjacent normal breast tissue array (2012 WHO classification), including pathology grade, TNM and clinical stage (AJCC 7th edition), 12 cases/24 cores, repalcing BR245. Breast carcinoma with adjacent normal breast tissue microarray, containing 10 cases of invasive carcinoma of no special type, 2 adjacent normal breast tissue, duplicate cores per ...
Manufactured by:Pepex Biomedical, Inc. based inNorcross, GEORGIA (US) (USA)
3E Catheter Style Sensor Module for In-Hospital Diagnostics for Trend Monitoring for In-Hospital Diagnostics. ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
AV-353 is the Company’s potent, selective, high affinity inhibitory antibody specific to Notch 3. The Notch 3 signaling pathway is important in cell-to-cell communication involving gene regulation mechanisms that control multiple cell differentiation processes during the entire life cycle. Scientific literature has implicated the Notch 3 receptor pathway in multiple diseases, including ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. A broader window of opportunity. Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy. ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite of proprietary cytotoxins (cell-killing compounds), ...
Manufactured by:Virtual Incision based inLincoln, NEVADA (USA)
MIRA’s convenient, capable, compact design empowers surgeons to quickly obtain full multi-quadrant access and work closer to the ...
by:Alfa Cytology based inU.S. VIRGIN ISLANDS
Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used to study Axl-related diseases, such as cancer (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer and glioma), kidney disease, immune system disease and cardiovascular disease. ...
Manufactured by:Neuros Medical, Inc. based inWilloughby Hills, OHIO (USA)
A growing amputee population: There are over two million people estimated to be living with limb loss in the United States today, and almost 185,000 people have an amputation each year.1 Causes of amputation include peripheral vascular disease, trauma, and cancer.1 Worse yet, the number of amputees is expected to double by ...
by:Sirenas based inSan Diego, CALIFORNIA (USA)
The Global Leader in the Discovery of Natural Product Chemistry for Healthcare. Sirenas prides itself on being at the forefront of computational metabolomics for chemical discovery. Our deep experience and historical productivity indicate that these cutting-edge tools, when applied to living systems, can generate the insights necessary to forge new classes of therapeutics and health products. ...
Manufactured by:MiMedx Group, Inc. based inMarietta, GEORGIA (US) (USA)
The placental membrane may be repurposed after delivery as a semi-permeable protective barrier that supports the healing cascade. For patients with challenging wounds (e.g. non-healing ulcers) or requiring surgical procedures, placental-based therapies are a valuable treatment option. Clinical evidence from many randomized clinical trials have demonstrated that placental-based allografts provide ...
Manufactured by:GeneCentric Therapeutics, Inc. based inDurham, NORTH CAROLINA (USA)
Head and Neck Cancer, a group of cancers that starts within the mouth, nose, throat, larynx, sinuses, or salivary glands, is the seventh most common of all cancers. Because most majority begin in squamous cells which line the moist surfaces inside the head and neck areas, such cancers are also referred to as Head and Neck Squamous Cell Carcinomas ...
Manufactured by:Caprico Biotechnologies, Inc. (CBI) based inNorcross, GEORGIA (US) (USA)
EAPII (also called TTRAP, TDP2) originally was identified as an interacting partner of oncogene ETS1, a founding member of ets transcription factor, and the cytoplasmic domain of CD40, a member of the tumor necrosis factor (TNF) receptor family. EAPII significantly represses ETS1 transcriptional activity and the synergistic transactivation by ETS1 and AP-1 or by ETS1 and NFκB. EAPII/TTRAP ...
Manufactured by:Sano Diagnostics LLC based inWellesley Heights, MASSACHUSETTS (USA)
Simplifying detection of Inflammatory Markers relevant to multiple diseases. SANO Diagnostics’ technology is founded on the ability to detect certain markers of inflammation, a class of proteins known as ...
Manufactured by:Immudex ApS based inVirum, DENMARK
Antigen-specific CD8+ T cells play an important role in the immune response of autoimmune disease, cancer, transplantation, infectious disease, and allergy. MHC I Dextramer® reagents can identify antigen-specific CD8+ T cell subsets by flow cytometry. MHC I Dextramer reagents consist of a protein-stabilizing dextran backbone, an optimized number of MHC-peptide complexes, and fluorophores (PE, ...
Manufactured by:Kalaris based inWaltham, MASSACHUSETTS (USA)
Kalaris Therapeutics is focused on developing innovative treatments for retinal diseases, aiming to reduce the burden of frequent clinical visits for patients with retinal neovascular and exudative conditions. Their lead product, TH103, is a fully humanized, recombinant fusion protein designed for intravitreal delivery as an anti-VEGF agent. TH103 functions as a soluble decoy receptor, ...
Manufactured by:Moderna, Inc. based inCambridge, MASSACHUSETTS (USA)
At Moderna, we are delivering on the promise of mRNA science to create a new generation of transformative medicines for ...